-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Finance App News, Columbotai Bio-B (06990.HK) announced that the company's three products, namely ADC Sacituzumab Tirumotecan (SAC-TMT, also known as SKB264/MK-2870) (trade name: Cathay Lai®), cetuximab N01 injection (formerly A140) (trade name: Datailai®), and Tagitanlimab (also known as A167) (trade name: Cotailai®), have been included in the National Health Security Administration and the Ministry of Human Resources and Social Security of China The national health insurance catalogue was announced on December 7, 2025. Notably, ADC Sacituzumab Tirumotecan has two indications included in the national health insurance catalogue.

Zhitongcaijing·12/15/2025 13:09:11
Listen to the news
Zhitong Finance App News, Columbotai Bio-B (06990.HK) announced that the company's three products, namely ADC Sacituzumab Tirumotecan (SAC-TMT, also known as SKB264/MK-2870) (trade name: Cathay Lai®), cetuximab N01 injection (formerly A140) (trade name: Datailai®), and Tagitanlimab (also known as A167) (trade name: Cotailai®), have been included in the National Health Security Administration and the Ministry of Human Resources and Social Security of China The national health insurance catalogue was announced on December 7, 2025. Notably, ADC Sacituzumab Tirumotecan has two indications included in the national health insurance catalogue.